Impression Healthcare: Commences ARDS animal study
- Impression Healthcare has commenced an animal study for the treatment of sepsis-associated acute respiratory distress syndrome (SAARDS)
- SAARDS is the leading cause of death associated with COVID-19, due to a runaway immune response which causes organ and tissue damage
- Impression has filed a provisional patent for IHL-675A, a combination drug incorporating cannabidiol and hydroxychloroquine
- Then the treatment aimed at suppressing the body’s hyperinflammation response, known as a cytokine storm
- There is currently no approved pharmacological treatment for SAARDS, which has been an unmet medical also need for decades
- Impression Healthcare is up a slight 1.96 per cent and shares are trading at 5.2 cents each
